Report of the national heart, lung and blood institute-national institute of allergy and infectious diseases working group on antimicrobial strategies and cardiothoracic surgery

American Heart Journal

Volumn 147, Issue 4, 2004, Pages 575-581

  Lowy, Franklin D ^a   Waldhausen, John A ^b   Miller, Marissa ^c   Sopko, George ^d   Rosenberg, Yves ^d   Skarlatos, Sonia I ^d  

^a Columbia University ^*  (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; HUMAN MONOCLONAL ANTIBODY; LINEZOLID; LIPOPEPTIDE; LYSOSTAPHIN; MONOCLONAL ANTIBODY; ORITAVANCIN; STAPHYLOCOCCUS VACCINE; VANCOMYCIN;

ACTIVE IMMUNIZATION; AGING; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; CARDIOVASCULAR INFECTION; CLINICAL TRIAL; COMORBIDITY; EPIDEMIOLOGICAL DATA; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; MORBIDITY; MORTALITY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTHESIS INFECTION; REOPERATION; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; SURGICAL TECHNIQUE; THORAX SURGERY; TREATMENT OUTCOME; WOUND INFECTION;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DATABASES, FACTUAL; HUMANS; POSTOPERATIVE COMPLICATIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 3142618403     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.08.016     Document Type: Article

References (32)

1. Banerjee S.N., Emori T.G., Culver D.H., et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med. 91:1991;86-89S
2. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control. 27:1999;520-532
3. Grover F.L., Shroyer A.L., Hammermeister K., et al. A decade's experience with quality improvement in cardiac surgery using the Veterans Affairs and Society of Thoracic Surgeons national databases. Ann Surg. 234:2001;464-474
4. Ferguson T.B. Jr, Hammill B.G., Peterson E.D., et al. A decade of change - risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999 A report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg. 73:2002;480-490
5. Cabell C.H., Jollis J.G., Peterson G.E., et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med. 162:2002;90-94
6. Chien Y., Cheung A.L. Molecular interactions between two global regulators, sar and agr, in Staphylococcus aureus. J Biol Chem. 273:1998;2645-2652
7. Cheung A.L., Zhang G. Global regulation of virulence determinants in Staphylococcus aureus by the SarA protein family. Front Biosci. 7:2002;d1825-1842
8. Cheung A.L., Eberhardt K.J., Chung E., et al. Diminished virulence of a sar-/agr- mutant of Staphylococcus aureus in the rabbit model of endocarditis. J Clin Invest. 94:1994;1815-1822
9. Massey R.C., Kantzanou M.N., Fowler T., et al. Fibronectin-binding protein A of Staphylococcus aureus has multiple, substituting, binding regions that mediate adherence to fibronectin and invasion of endothelial cells. Cell Microbiol. 3:2001;839-851
10. Miyamoto Y.J., Wann E.R., Fowler T., et al. Fibronectin binding protein A of Staphylococcus aureus can mediate human T lymphocyte adhesion and coactivation. J Immunol. 166:2001;5129-5138
11. Hartford O.M., Wann E.R., Hook M., et al. Identification of residues in the Staphylococcus aureus fibrinogen-binding MSCRAMM clumping factor A (ClfA) that are important for ligand binding. J Biol Chem. 276:2001;2466-2473
12. Patti J.M., Allen B.L., McGavin M.J., et al. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol. 48:1994;585-617
13. O'Brien L., Kerrigan S.W., Kaw G., et al. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus Roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol Microbiol. 44:2002;1033-1044
14. Hiramatsu K., Hanaki H., Ino T., et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136
15. Centers for Disease Control and Prevention. Vancomycin resistant Staphylococcus aureus - Pennsylvania, 2002. JAMA. 288:2002;2116
16. Kluytmans J.A., Mouton J.W., Ijzerman E.P., et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis. 171:1995;216-219
17. Cimochowski G.E., Harostock M.D., Brown R., et al. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg. 71:2001;1572-1579
18. Perl T.M., Cullen J.J., Wenzel R.P., et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 346:2002;1871-1877
19. Moellering R.C. Linezolid The first oxazolidinone antimicrobial. Ann Intern Med. 138:2003;135-142
20. Tsiodras S., Gold H.S., Sakoulas G., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 358:2001;207-208
21. Allington D.R., Rivey M.P. Quinupristin/dalfopristin A therapeutic review. Clin Ther. 23:2001;24-44
22. Bhavnani S.M., Ballow C.H. New agents for gram-positive bacteria. Curr Opin Microbiol. 3:2000;528-534
23. Critchley I.A., Blosser-Middleton R.S., Jones M.E., et al. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother. 47:2003;1689-1693
24. Abbanat D., Macielag M., Bush K. Novel antibacterial agents for the treatment of serious gram-positive infections. Expert Opinion Invest Drugs. 12:2003;379-399
25. Climo M.W., Patron R.L., Goldstein B.P., et al. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother. 42:1998;1355-1360
26. McDevitt D., Rosenberg M. Exploiting genomics to discover new antibiotics. Trends Microbiol. 9:2001;611-617
27. Nilsson I.M., Patti J.M., Bremell T., et al. Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Invest. 101:1998;2640-2649
28. Shinefield H., Black S., Fattom A., et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 346:2002;491-496
29. Sulakvelidze A., Alavidze Z., Morris J.G. Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 45:2001;649-659
30. Califf R.M., Woodlief L.H. Pragmatic and mechanistic trials. Eur Heart J. 18:1997;367-370
31. Hammermeister K., Sethi G.K., Henderson W.G., et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve Final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 36:2000;1152-1158
32. Ferguson T.B. Jr, Coombs L.P., Peterson E.D. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA. 287:2002;2221-2227